<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166637">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02098798</url>
  </required_header>
  <id_info>
    <org_study_id>REB13-0960</org_study_id>
    <nct_id>NCT02098798</nct_id>
  </id_info>
  <brief_title>Comparison of Surveillance Colonoscopy Techniques in Patients With IBD</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose a randomized controlled study to determine the detection rates of neoplasia with
      high definition colonoscopy alone, high definition dye spraying chromoendoscopy or High
      definition iSCAN virtual chromoendoscopy in patients with long standing colitis (8 years
      from diagnosis except primary sclerosing cholangitis when surveillance starts at diagnosis)
      CD or UC.

      We hypothesized that these novel endoscopic techniques using High definition colonoscopy
      with virtual chromoendoscopy  -iScan 2 and 3 may be  superior to high definition colonoscopy
      alone and similar to using dye spraying chromoendoscopy for detection of dysplasia and
      neoplasia in patients with long standing IBD.

      We will aim to demonstrate if we can avoid dye spraying during the procedure and save
      expense and considerable time.

      In addition, we can hope to produce evidence and inform the way in which we perform
      surveillance colonoscopy especially without large number of multiple random biopsies but
      only few  targeted&quot; smart and intelligent&quot; biopsies using high definition colonoscopy with
      iSCAN technique as is   already the European practice in several centres.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Detection of neoplasia in the 3 cohorts - high definition colonoscopy, HD colonoscopy + iSCAN, HD colonoscopy + dye chromoendoscopy</measure>
    <time_frame>At the time of procedure</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>HD</arm_group_label>
    <description>High Definition Colonoscopy alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HD + iSCAN</arm_group_label>
    <description>HD colonoscopy + iSCAN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HD + Dye</arm_group_label>
    <description>High definition colonoscopy + dye spraying chromoendoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HD Colonoscopy</intervention_name>
    <description>High definition colonoscopy procedure in surveillance colonoscopy</description>
    <arm_group_label>HD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HD Colonoscopy + iSCAN</intervention_name>
    <arm_group_label>HD + iSCAN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HD Colonoscopy + dye spray</intervention_name>
    <arm_group_label>HD + Dye</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Inflammatory bowel disease patients undergoing surveillance colonoscopy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical and histological  diagnosis of UC or colonic CD-extensive or pancolitis.

        UC -CD Disease duration 8 years from diagnosis UC-CD with associated primary sclerosing
        cholangitis from diagnosis Ulcerative Colitis Activity Index Mayo score 0-1 (inactive
        disease) Crohn's  disease  Activity Index - Harvey Bradshaw score &lt;4 (dysplasia detection
        requires quiescent inflammatory bowel disease)

        Exclusion Criteria:

        Known intraepithelial neoplasia or colorectal cancer or other neoplasia Coagulopathy which
        may prevent biopsies Pregnancy Inability to obtain informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marietta Iacucci, MD</last_name>
    <email>miacucci@ucalgary.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miriam Fort Gasia, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary, Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marietta Iacucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>March 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Iacucci Marietta  MD,PhD</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Dysplasia, Inflammatory Bowel Disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
